EA201692265A1 - Ингибиторы фосфатидилинозитол-3-киназы - Google Patents
Ингибиторы фосфатидилинозитол-3-киназыInfo
- Publication number
- EA201692265A1 EA201692265A1 EA201692265A EA201692265A EA201692265A1 EA 201692265 A1 EA201692265 A1 EA 201692265A1 EA 201692265 A EA201692265 A EA 201692265A EA 201692265 A EA201692265 A EA 201692265A EA 201692265 A1 EA201692265 A1 EA 201692265A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- phosphatidylinositol
- compounds
- kinase inhibitors
- application
- tautomers
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
Abstract
В настоящей заявке предложены соединения формулы (J)или их фармацевтически приемлемые соли, изомеры, таутомеры или их смеси, где n, m, R, R, R, Rи Rописаны в настоящей заявке. Соединения представляют собой ингибиторы активности фосфатидилинозитол-3-киназы (PI3K) и подходят для лечения состояний, опосредованных одной или более изоформами PI3K. В настоящей заявке дополнительно предложены фармацевтические композиции, содержащие соединение формулы (I) или его фармацевтически приемлемые соли, изомеры, таутомеры или их смеси, и способы применения указанных соединений и композиций для лечения состояний, опосредованных одной или более изоформами PI3K.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462011905P | 2014-06-13 | 2014-06-13 | |
PCT/US2015/035161 WO2015191754A2 (en) | 2014-06-13 | 2015-06-10 | Phosphatidylinositol 3-kinase inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
EA201692265A1 true EA201692265A1 (ru) | 2017-05-31 |
Family
ID=54545432
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA201692265A EA201692265A1 (ru) | 2014-06-13 | 2015-06-10 | Ингибиторы фосфатидилинозитол-3-киназы |
Country Status (17)
Country | Link |
---|---|
US (1) | US9499523B2 (ru) |
EP (1) | EP3154962B1 (ru) |
JP (1) | JP6346964B2 (ru) |
KR (1) | KR20170012558A (ru) |
CN (1) | CN106573922A (ru) |
AR (1) | AR100810A1 (ru) |
AU (1) | AU2015274637B2 (ru) |
BR (1) | BR112016028814A2 (ru) |
CA (1) | CA2952044C (ru) |
EA (1) | EA201692265A1 (ru) |
ES (1) | ES2750357T3 (ru) |
IL (1) | IL249079A0 (ru) |
MX (1) | MX2016016517A (ru) |
NZ (1) | NZ726638A (ru) |
SG (1) | SG11201610088XA (ru) |
TW (1) | TW201627303A (ru) |
WO (1) | WO2015191754A2 (ru) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2952037A1 (en) | 2014-06-13 | 2015-12-17 | Gilead Sciences, Inc. | Phosphatidylinositol 3-kinase inhibitors |
MX2016016528A (es) | 2014-06-13 | 2017-03-27 | Gilead Sciences Inc | Inhibidores de fosfatidilinositol 3-quinasa. |
SG11201609527PA (en) | 2014-06-13 | 2016-12-29 | Gilead Sciences Inc | Quinazolinone derivatives as phosphatidylinositol 3-kinase inhibitors |
CN106459005A (zh) | 2014-06-13 | 2017-02-22 | 吉利德科学公司 | 磷脂酰肌醇3‑激酶抑制剂 |
CN106573922A (zh) | 2014-06-13 | 2017-04-19 | 吉利德科学公司 | 磷脂酰肌醇3‑激酶抑制剂 |
DK3236972T3 (en) | 2014-12-26 | 2021-10-04 | Univ Emory | Antivirale N4-hydroxycytidin-derivativer |
TWI808055B (zh) | 2016-05-11 | 2023-07-11 | 美商滬亞生物國際有限公司 | Hdac 抑制劑與 pd-1 抑制劑之組合治療 |
TWI794171B (zh) | 2016-05-11 | 2023-03-01 | 美商滬亞生物國際有限公司 | Hdac抑制劑與pd-l1抑制劑之組合治療 |
TW201813963A (zh) | 2016-09-23 | 2018-04-16 | 美商基利科學股份有限公司 | 磷脂醯肌醇3-激酶抑制劑 |
TW201815787A (zh) * | 2016-09-23 | 2018-05-01 | 美商基利科學股份有限公司 | 磷脂醯肌醇3-激酶抑制劑 |
TW201825465A (zh) | 2016-09-23 | 2018-07-16 | 美商基利科學股份有限公司 | 磷脂醯肌醇3-激酶抑制劑 |
SG11202004403QA (en) | 2017-12-07 | 2020-06-29 | Univ Emory | N4-hydroxycytidine and derivatives and anti-viral uses related thereto |
KR20200112900A (ko) | 2018-01-20 | 2020-10-05 | 선샤인 레이크 파르마 컴퍼니 리미티드 | 치환된 아미노피리미딘 화합물 및 이의 사용 방법 |
PE20230376A1 (es) * | 2019-12-24 | 2023-03-06 | Carna Biosciences Inc | Compuestos moduladores de la diacilglicerol quinasa |
Family Cites Families (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
US4326525A (en) | 1980-10-14 | 1982-04-27 | Alza Corporation | Osmotic device that improves delivery properties of agent in situ |
US5364620A (en) | 1983-12-22 | 1994-11-15 | Elan Corporation, Plc | Controlled absorption diltiazem formulation for once daily administration |
US5023252A (en) | 1985-12-04 | 1991-06-11 | Conrex Pharmaceutical Corporation | Transdermal and trans-membrane delivery of drugs |
US5001139A (en) | 1987-06-12 | 1991-03-19 | American Cyanamid Company | Enchancers for the transdermal flux of nivadipine |
US4992445A (en) | 1987-06-12 | 1991-02-12 | American Cyanamid Co. | Transdermal delivery of pharmaceuticals |
US4965288A (en) | 1988-02-25 | 1990-10-23 | Merrell Dow Pharmaceuticals Inc. | Inhibitors of lysyl oxidase |
US5021456A (en) | 1988-02-25 | 1991-06-04 | Merrell Dow Pharmaceuticals Inc. | Inhibitors of lysyl oxidase |
US5059714A (en) | 1988-02-25 | 1991-10-22 | Merrell Dow Pharmaceuticals Inc. | Inhibitors of lysyl oxidase |
US4943593A (en) | 1988-02-25 | 1990-07-24 | Merrell Dow Pharmaceuticals Inc. | Inhibitors of lysyl oxidase |
US5252608A (en) | 1988-02-25 | 1993-10-12 | Merrell Dow Pharmaceuticals Inc. | Inhibitors of lysyl oxidase |
US5182297A (en) | 1988-02-25 | 1993-01-26 | Merrell Dow Pharmaceuticals Inc. | Inhibitors of lysyl oxidase |
US4902514A (en) | 1988-07-21 | 1990-02-20 | Alza Corporation | Dosage form for administering nilvadipine for treating cardiovascular symptoms |
US5120764A (en) | 1988-11-01 | 1992-06-09 | Merrell Dow Pharmaceuticals Inc. | Inhibitors of lysyl oxidase |
US4997854A (en) | 1989-08-25 | 1991-03-05 | Trustees Of Boston University | Anti-fibrotic agents and methods for inhibiting the activity of lysyl oxidase in-situ using adjacently positioned diamine analogue substrates |
US6667300B2 (en) * | 2000-04-25 | 2003-12-23 | Icos Corporation | Inhibitors of human phosphatidylinositol 3-kinase delta |
SI2223922T1 (sl) | 2000-04-25 | 2016-04-29 | Icos Corporation | Inhibitorji humane fosfatidil-inositol 3-kinazne delta izoforme |
FR2828206B1 (fr) | 2001-08-03 | 2004-09-24 | Centre Nat Rech Scient | Utilisation d'inhibiteurs des lysyl oxydases pour la culture cellulaire et le genie tissulaire |
BRPI0808888B8 (pt) | 2007-03-12 | 2021-05-25 | Cytopia Res Pty Ltd | composto de fenil amino pirimidina para uso no tratamento de uma doença associada à quinase, processo para a preparação do composto, composição farmacêutica, e, implante |
US8450321B2 (en) | 2008-12-08 | 2013-05-28 | Gilead Connecticut, Inc. | 6-(1H-indazol-6-yl)-N-[4-(morpholin-4-yl)phenyl]imidazo-[1,2-A]pyrazin-8-amine, or a pharmaceutically acceptable salt thereof, as a SYK inhibitor |
US8399460B2 (en) | 2009-10-27 | 2013-03-19 | Astrazeneca Ab | Chromenone derivatives |
KR101758046B1 (ko) * | 2009-12-22 | 2017-07-14 | 버텍스 파마슈티칼스 인코포레이티드 | 포스파티딜이노시톨 3-키나제의 이소인돌리논 억제제 |
MX2012013622A (es) | 2010-05-31 | 2013-02-01 | Ono Pharmaceutical Co | Derivado de purinona. |
US9670212B2 (en) * | 2010-09-14 | 2017-06-06 | Exelixis, Inc. | Inhibitors of PI3K-delta and methods of their use and manufacture |
ES2714384T3 (es) | 2010-10-06 | 2019-05-28 | Glaxosmithkline Llc | Derivados de bencimidazol como inhibidores de PI3 quinasa |
LT2658844T (lt) | 2010-12-28 | 2017-02-10 | Sanofi | Nauji pirimidino dariniai, jų gamyba ir jų farmacinis panaudojimas kaip akt (pkb) fosforilinimo slopiklių |
EP2518070A1 (en) * | 2011-04-29 | 2012-10-31 | Almirall, S.A. | Pyrrolotriazinone derivatives as PI3K inhibitors |
CA2952037A1 (en) | 2014-06-13 | 2015-12-17 | Gilead Sciences, Inc. | Phosphatidylinositol 3-kinase inhibitors |
CN106459005A (zh) | 2014-06-13 | 2017-02-22 | 吉利德科学公司 | 磷脂酰肌醇3‑激酶抑制剂 |
CN106573922A (zh) | 2014-06-13 | 2017-04-19 | 吉利德科学公司 | 磷脂酰肌醇3‑激酶抑制剂 |
SG11201609527PA (en) | 2014-06-13 | 2016-12-29 | Gilead Sciences Inc | Quinazolinone derivatives as phosphatidylinositol 3-kinase inhibitors |
MX2016016528A (es) | 2014-06-13 | 2017-03-27 | Gilead Sciences Inc | Inhibidores de fosfatidilinositol 3-quinasa. |
-
2015
- 2015-06-10 CN CN201580031602.6A patent/CN106573922A/zh active Pending
- 2015-06-10 AU AU2015274637A patent/AU2015274637B2/en not_active Ceased
- 2015-06-10 ES ES15795017T patent/ES2750357T3/es active Active
- 2015-06-10 US US14/736,025 patent/US9499523B2/en active Active
- 2015-06-10 KR KR1020177000693A patent/KR20170012558A/ko not_active Application Discontinuation
- 2015-06-10 EP EP15795017.1A patent/EP3154962B1/en active Active
- 2015-06-10 SG SG11201610088XA patent/SG11201610088XA/en unknown
- 2015-06-10 NZ NZ726638A patent/NZ726638A/en not_active IP Right Cessation
- 2015-06-10 CA CA2952044A patent/CA2952044C/en not_active Expired - Fee Related
- 2015-06-10 EA EA201692265A patent/EA201692265A1/ru unknown
- 2015-06-10 MX MX2016016517A patent/MX2016016517A/es unknown
- 2015-06-10 WO PCT/US2015/035161 patent/WO2015191754A2/en active Application Filing
- 2015-06-10 JP JP2016572435A patent/JP6346964B2/ja not_active Expired - Fee Related
- 2015-06-10 BR BR112016028814A patent/BR112016028814A2/pt not_active IP Right Cessation
- 2015-06-11 AR ARP150101860A patent/AR100810A1/es unknown
- 2015-06-12 TW TW104119194A patent/TW201627303A/zh unknown
-
2016
- 2016-11-21 IL IL249079A patent/IL249079A0/en unknown
Also Published As
Publication number | Publication date |
---|---|
CN106573922A (zh) | 2017-04-19 |
ES2750357T3 (es) | 2020-03-25 |
SG11201610088XA (en) | 2016-12-29 |
IL249079A0 (en) | 2017-01-31 |
CA2952044C (en) | 2019-01-29 |
US9499523B2 (en) | 2016-11-22 |
TW201627303A (zh) | 2016-08-01 |
US20150361071A1 (en) | 2015-12-17 |
MX2016016517A (es) | 2017-05-01 |
NZ726638A (en) | 2018-04-27 |
JP2017517544A (ja) | 2017-06-29 |
EP3154962B1 (en) | 2019-08-07 |
AU2015274637A1 (en) | 2016-12-08 |
WO2015191754A3 (en) | 2016-02-11 |
AU2015274637B2 (en) | 2018-04-19 |
BR112016028814A2 (pt) | 2017-08-22 |
WO2015191754A2 (en) | 2015-12-17 |
CA2952044A1 (en) | 2015-12-17 |
EP3154962A2 (en) | 2017-04-19 |
AR100810A1 (es) | 2016-11-02 |
JP6346964B2 (ja) | 2018-06-20 |
KR20170012558A (ko) | 2017-02-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA201692249A1 (ru) | Ингибиторы фосфатидилинозитол-3-киназы | |
EA201692265A1 (ru) | Ингибиторы фосфатидилинозитол-3-киназы | |
EA201692266A1 (ru) | Ингибиторы фосфатидилинозитол-3-киназы | |
EA201692487A1 (ru) | Ингибиторы фосфатидилинозитол-3-киназы | |
EA201592182A1 (ru) | Ингибиторы фосфатидилинозитол-3-киназы | |
EA201692267A1 (ru) | Ингибиторы фосфатидилинозитол-3-киназы | |
EA201692268A1 (ru) | Ингибиторы фосфатидилинозитол-3-киназы | |
PH12016502382A1 (en) | Substituted indazole compounds as irak4 inhibitors | |
EA201691803A1 (ru) | Ингибиторы калликреина плазмы человека | |
PH12017500583A1 (en) | Dihydropyrrolopyridine inhibitors of ror-gamma | |
PH12016501457A1 (en) | Dihydropyrrolopyridine inhibitors of ror-gamma | |
EA201791256A1 (ru) | Производные хиназолина, применяемые для лечения вич | |
EA201691302A1 (ru) | Новые гетероциклические соединения | |
NZ736709A (en) | Benzimidazole and imidazopyridine carboximidamide compounds having activity as inhibitors of indoleamine 2,3-dioxygenase | |
EA201790395A1 (ru) | Производные аминотриазина, подходящие для применения в качестве соединений-ингибиторов tank-связывающей киназы | |
MX2016015565A (es) | Ciertos inhibidores de la proteina quinasa. | |
EA201790599A1 (ru) | Соединения и композиции в качестве ингибиторов киназ | |
EA201692143A1 (ru) | Производные аминопиразина в качестве ингибиторов фосфатидилинозитол-3-киназы | |
EA201692000A1 (ru) | Макроциклические производные пиридина | |
EA201692313A1 (ru) | Производные индолизина в качестве ингибиторов фосфоинозитид-3-киназ | |
EA201692003A1 (ru) | Макроциклические производные пиримидина | |
SA519410093B1 (ar) | مركبات بيريميدو بيريميدينون مفيدة كمثبطات دبليو إى إى-1 كيناز | |
BR112017002852A2 (pt) | compostos de azetidiniloxifenilpirrolidina | |
EA201792265A1 (ru) | Способы лечения сердечно-сосудистых заболеваний | |
EA202091668A2 (ru) | Ингибиторы калликреина плазмы человека |